X

Quality Statement

Pacific Biosciences is committed to providing high-quality products that meet customer expectations and comply with regulations. We will achieve these goals by adhering to and maintaining an effective quality-management system designed to ensure product quality, performance, and safety.

X

Image Use Agreement

By downloading, copying, or making any use of the images located on this website (“Site”) you acknowledge that you have read and understand, and agree to, the terms of this Image Usage Agreement, as well as the terms provided on the Legal Notices webpage, which together govern your use of the images as provided below. If you do not agree to such terms, do not download, copy or use the images in any way, unless you have written permission signed by an authorized Pacific Biosciences representative.

Subject to the terms of this Agreement and the terms provided on the Legal Notices webpage (to the extent they do not conflict with the terms of this Agreement), you may use the images on the Site solely for (a) editorial use by press and/or industry analysts, (b) in connection with a normal, peer-reviewed, scientific publication, book or presentation, or the like. You may not alter or modify any image, in whole or in part, for any reason. You may not use any image in a manner that misrepresents the associated Pacific Biosciences product, service or technology or any associated characteristics, data, or properties thereof. You also may not use any image in a manner that denotes some representation or warranty (express, implied or statutory) from Pacific Biosciences of the product, service or technology. The rights granted by this Agreement are personal to you and are not transferable by you to another party.

You, and not Pacific Biosciences, are responsible for your use of the images. You acknowledge and agree that any misuse of the images or breach of this Agreement will cause Pacific Biosciences irreparable harm. Pacific Biosciences is either an owner or licensee of the image, and not an agent for the owner. You agree to give Pacific Biosciences a credit line as follows: "Courtesy of Pacific Biosciences of California, Inc., Menlo Park, CA, USA" and also include any other credits or acknowledgments noted by Pacific Biosciences. You must include any copyright notice originally included with the images on all copies.

IMAGES ARE PROVIDED BY Pacific Biosciences ON AN "AS-IS" BASIS. Pacific Biosciences DISCLAIMS ALL REPRESENTATIONS AND WARRANTIES, EXPRESS, IMPLIED OR STATUTORY, INCLUDING, BUT NOT LIMITED TO, NON-INFRINGEMENT, OWNERSHIP, MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE. IN NO EVENT SHALL Pacific Biosciences BE LIABLE FOR ANY DIRECT, INDIRECT, INCIDENTAL, PUNITIVE, OR CONSEQUENTIAL DAMAGES OF ANY KIND WHATSOEVER WITH RESPECT TO THE IMAGES.

You agree that Pacific Biosciences may terminate your access to and use of the images located on the PacificBiosciences.com website at any time and without prior notice, if it considers you to have violated any of the terms of this Image Use Agreement. You agree to indemnify, defend and hold harmless Pacific Biosciences, its officers, directors, employees, agents, licensors, suppliers and any third party information providers to the Site from and against all losses, expenses, damages and costs, including reasonable attorneys' fees, resulting from any violation by you of the terms of this Image Use Agreement or Pacific Biosciences' termination of your access to or use of the Site. Termination will not affect Pacific Biosciences' rights or your obligations which accrued before the termination.

I have read and understand, and agree to, the Image Usage Agreement.

I disagree and would like to return to the Pacific Biosciences home page.

Pacific Biosciences
Contact:

Pacific Biosciences Announces Fourth Quarter 2015 Financial Results

Wednesday, February 3, 2016

MENLO PARK, Calif., Feb. 03, 2016 (GLOBE NEWSWIRE) — Pacific Biosciences of California, Inc. (NASDAQ:PACB) today announced financial results for its fourth quarter ended December 31, 2015.

Revenue for the fourth quarter of 2015 increased 115% to $36.3 million, compared to $16.9 million for the fourth quarter of 2014. Fourth quarter 2015 revenue includes product and service revenue of $12.7 million and $23.6 million of contractual revenue, while fourth quarter 2014 revenue includes product and service revenue of $15.2 million and $1.7 million of contractual revenue. Fourth quarter 2015 contractual revenue includes a $20.0 million milestone from Roche and $3.6 million of quarterly amortization of the upfront Roche payment, while fourth quarter 2014 contractual revenue reflects $1.7 million of quarterly amortization of the upfront Roche payment.

Gross profit increased $22.1 million to $26.5 million for the fourth quarter of 2015, resulting in a gross margin of 72.9%, compared to gross profit of $4.4 million and a gross margin of 26.3% for the fourth quarter of 2014. The growth in gross profit and margin was primarily driven by an additional $21.9 million of contractual revenue from Roche, which has a gross margin of 100%.

Operating expenses totaled $27.5 million for the fourth quarter of 2015, compared to $22.3 million for the fourth quarter of 2014. Operating expenses for the fourth quarters of 2015 and 2014 included non-cash stock-based compensation of $3.6 million and $2.7 million, respectively.

The net loss for the fourth quarter of 2015 was $1.4 million, compared to $19.0 million for the fourth quarter of 2014.

Cash, cash equivalents and investments, excluding restricted cash at December 31, 2015 totaled $82.3 million, compared to $101.3 million at December 31, 2014

Quarterly Conference Call Information 

Management will host a quarterly conference call to discuss its fourth quarter 2015 results today at 4:30 p.m. Eastern Time. Investors may listen to the call by dialing 1.888.366.7247, or if outside the U.S., by dialing +1.707.287.9330. The call will be webcast live and will be available for replay at Pacific Biosciences’ website at http://investor.pacificbiosciences.com/ .

About Pacific Biosciences

Pacific Biosciences of California, Inc. (NASDAQ:PACB) offers sequencing systems to help scientists resolve genetically complex problems. Based on its novel Single Molecule, Real-Time (SMRT®) Technology, Pacific Biosciences’ products enable: de novo genome assembly to finish genomes in order to more fully identify, annotate and decipher genomic structures; full-length transcript analysis to improve annotations in reference genomes, characterize alternatively spliced isoforms in important gene families, and find novel genes; targeted sequencing to more comprehensively characterize genetic variations; and DNA base modification identification to help characterize epigenetic regulation and DNA damage. Pacific Biosciences’ technology provides the industry’s highest consensus accuracy over the longest read lengths in combination with the ability to detect real-time kinetic information. PacBio® sequencing systems, including consumables and software, provide a simple, fast, end-to-end workflow for SMRT Sequencing.  More information is available at www.pacb.com

Forward-Looking Statements
All statements in this press release that are not historical are forward-looking statements, including, among other things, statements relating to the timeline for Pacific Biosciences’ potential development of products for Roche, the attributes of the Sequel System and other future events. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, changes in circumstances and other factors that are, in some cases, beyond Pacific Biosciences’ control and could cause actual results to differ materially from the information expressed or implied by forward-looking statements made in this press release. Factors that could materially affect actual results can be found in Pacific Biosciences’ most recent filings with the Securities and Exchange Commission, including Pacific Biosciences’ most recent reports on Forms 8-K, 10-K and 10-Q, and include those listed under the caption “Risk Factors.” Pacific Biosciences undertakes no obligation to revise or update information in this press release to reflect events or circumstances in the future, even if new information becomes available.
 

                       
Pacific Biosciences of California, Inc.
Unaudited Condensed Consolidated Statement of Operations
(amounts in thousands, except per share amounts)
                        
  Three-month Periods Ended
  Twelve-month Periods Ended
  December 31,
  December 31,
  2015
  2014    2015
  2014 
Revenue:                                                   
Product revenue $    9,799     $    12,923     $    37,502     $    35,299  
Service and other revenue      2,886          2,285          10,896          8,511  
Contractual revenue      23,596          1,696          44,384          16,784  
Total revenue      36,281          16,904          92,782          60,594  
Cost of Revenue:                      
Cost of product revenue      7,415          10,578          30,704          29,626  
Cost of service and other revenue      2,400          1,888          8,628          7,566  
Total cost of revenue      9,815          12,466    
 
   39,332          37,192  
  Gross profit      26,466          4,438          53,450          23,402  
Operating Expense:                      
Research and development      14,752          12,331          60,440          48,230  
Sales, general and administrative      12,776          10,001          45,187          38,026  
Gain on lease amendments                      (23,043 )        
Total operating
expense
     27,528          22,332          82,584          86,256  
Operating loss      (1,062 )        (17,894 )        (29,134 )        (62,854 )
Interest expense      (773 )        (725 )        (2,926 )        (2,828 )
Other
income (expense), net
     426          (356 )        364          (478 )
Net loss $    (1,409 )   $    (18,975 )   $    (31,696 )   $    (66,160 )
Basic and diluted net loss per share $    (0.02 )   $    (0.26 )   $    (0.42 )   $    (0.94 )
Shares used in computing basic and diluted net loss per share        78,327          72,729          75,614          70,475  
                                       

 

           
Pacific Biosciences of California, Inc.
Unaudited Condensed Consolidated Balance Sheets
(amounts in thousands)
           
  December 31,   December 31,
  2015   2014
Assets      
Cash and investments $  82,270   $  101,348
Accounts receivable    5,245      3,406
Inventory    10,955      11,335
Prepaid and other current assets    12,071      1,671
Property and equipment    8,548      6,601
Long-term restricted cash    4,500      —
Other long-term Assets    7,518      29
Total Assets $  131,107   $  124,390
           
Liabilities and Stockholders’ Equity          
Accounts payable $  4,749   $  5,608
Accrued expenses    15,551      11,441
Deferred service revenue    7,958      7,250
Deferred
contractual revenue
   12,134      26,520
Other liabilities    1,627      3,687
Financing derivative    600      944
Notes payable    14,948      13,991
Stockholders’ equity    73,540      54,949
Total Liabilities and Stockholders’ Equity   $  131,107   $  124,390
           

 

Contact:

Trevin Rard

650.521.8450

ir@pacificbiosciences.com

Primary Logo

Source: Pacific Biosciences, Inc.

News Provided by Acquire Media